Moreover, administration of IL-22 inhibits HSC activation, reduces the production of pro-inflammatory factors (IL-1β, IL-6, and TNF-α), and ameliorates liver fibrosis in CCl4-induced liver fibrosis (61). This evidence concerns the gene IL6 and Hepatic fibrosis.